A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

Official Title

A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Assess the Safety, Tolerability and Efficacy of Oral Ketamine for Patients With Rett Syndrome

Brief Summary

      This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and
      efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a
      4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort
      are anticipated to participate for approximately 8-10 weeks at approximately 7 US study
      centers.
    

Detailed Description

      This study is designed to assess oral ketamine for the treatment of Rett Syndrome and
      consists of up to 4 ascending dose cohorts, each assessing 1 dose level of ketamine vs
      placebo. Patients will receive in either order, a 5-day BID regimen of both placebo and the
      cohort-specified dose level of oral ketamine. Patients may only participate in 1 cohort.
      Safety and tolerability will be assessed via patient disposition, vital signs, physical
      examination, adverse events and concomitant medication use. Efficacy will be assessed via
      physician and caregiver questionnaires and assessments, and continuous, wearable, at-home
      biosensor data collection. An independent safety committee will review safety data from each
      cohort to determine if the subsequent ascending dose cohort is warranted. A total of 12
      patients per cohort is anticipated at approximately 7 sites. The screening period will last
      between 2 and 4 weeks, the cross-over treatment period will last 4 weeks, and the safety
      follow-up period will last 2 weeks. Total patient participation is approximately 8-10 weeks.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Dose-Limiting Adverse Events

Secondary Outcome

 Clinical Global Impression of Improvement

Condition

Rett Syndrome

Intervention

Ketamine

Study Arms / Comparison Groups

 0.75 mg/kg
Description:  ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

24

Start Date

March 12, 2019

Completion Date

November 22, 2021

Primary Completion Date

November 8, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Female Rett Syndrome patients diagnosed with Rett Syndrome with a confirmed MECP2
             mutation

          -  between the ages of 6 and 12, inclusive, who have not achieved menarche

          -  ability to take oral medications

          -  are generally healthy.

        Exclusion Criteria:

          -  Patients not on stable medication regimens/other types of behavioral, educational, or
             dietary interventions for at least 4 weeks,

          -  are taking medications that may interact with ketamine,

          -  have a condition where increased blood pressure, spinal fluid pressure, or ocular
             pressure may put the patient at increased risk.
      

Gender

Female

Ages

6 Years - 12 Years

Accepts Healthy Volunteers

No

Contacts

Jeffrey Neul, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03633058

Organization ID

Ket-101-RSRT


Responsible Party

Sponsor

Study Sponsor

Rett Syndrome Research Trust

Collaborators

 Vanderbilt University Medical Center

Study Sponsor

Jeffrey Neul, MD, PhD, Principal Investigator, Vanderbilt University Medical Center


Verification Date

April 2022